Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP594601.RAVI3aC04FE71BZLP4AZWqxGS8YwURo1mWXMHlbtRQvGI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP594601.RAVI3aC04FE71BZLP4AZWqxGS8YwURo1mWXMHlbtRQvGI130_assertion type Assertion NP594601.RAVI3aC04FE71BZLP4AZWqxGS8YwURo1mWXMHlbtRQvGI130_head.
- NP594601.RAVI3aC04FE71BZLP4AZWqxGS8YwURo1mWXMHlbtRQvGI130_assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP594601.RAVI3aC04FE71BZLP4AZWqxGS8YwURo1mWXMHlbtRQvGI130_provenance.
- NP594601.RAVI3aC04FE71BZLP4AZWqxGS8YwURo1mWXMHlbtRQvGI130_assertion evidence source_evidence_literature NP594601.RAVI3aC04FE71BZLP4AZWqxGS8YwURo1mWXMHlbtRQvGI130_provenance.
- NP594601.RAVI3aC04FE71BZLP4AZWqxGS8YwURo1mWXMHlbtRQvGI130_assertion SIO_000772 17308270 NP594601.RAVI3aC04FE71BZLP4AZWqxGS8YwURo1mWXMHlbtRQvGI130_provenance.
- NP594601.RAVI3aC04FE71BZLP4AZWqxGS8YwURo1mWXMHlbtRQvGI130_assertion wasDerivedFrom befree-2016 NP594601.RAVI3aC04FE71BZLP4AZWqxGS8YwURo1mWXMHlbtRQvGI130_provenance.
- NP594601.RAVI3aC04FE71BZLP4AZWqxGS8YwURo1mWXMHlbtRQvGI130_assertion wasGeneratedBy ECO_0000203 NP594601.RAVI3aC04FE71BZLP4AZWqxGS8YwURo1mWXMHlbtRQvGI130_provenance.